抗凝固療法の米国市場予測（～2022年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 10
1.1 OBJECTIVES OF THE STUDY 10
1.2 MARKET DEFINITION 10
1.3 MARKET SCOPE 11
1.3.1 MARKETS COVERED 11
1.3.2 YEARS CONSIDERED FOR THE STUDY 11
1.4 CURRENCY 12
1.5 STAKEHOLDERS 12
2 RESEARCH METHODOLOGY 13
2.1 RESEARCH APPROACH 13
2.1.1 SECONDARY DATA 14
2.1.2 PRIMARY DATA 15
2.1.2.1 Breakdown of primary interviews 16
2.1.2.2 Key industry insights 16
2.2 MARKET SIZE ESTIMATION 17
2.2.1 MARKET SIZING METHODOLOGY FOR ANTICOAGULATION DRUGS AND PT/INR TESTING DEVICES 18
2.2.2 MARKET SIZING METHODOLOGY FOR ANTICOAGULATION THERAPY FOR CLINICS 20
2.2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.2.4 MARKET SHARE ESTIMATION 22
2.2.5 ASSUMPTIONS FOR THE STUDY 22
3 MARKET OVERVIEW 23
3.1 MARKET DYNAMICS: ANTICOAGULATION DRUGS 23
3.1.1 DRIVERS 24
3.1.1.1 Rising incidence of venous thromboembolism, atrial fibrillation, and stroke 24
3.1.1.2 Increasing demand for NOACs as alternatives to warfarin 24
3.1.1.3 Growing number of patients requiring lifelong anticoagulation therapy 25
3.1.2 MARKET RESTRAINTS 25
3.1.2.1 High price of NOACs 25
3.1.2.2 High development expenditure, stringent regulations 26
3.1.3 MARKET OPPORTUNITIES 26
3.1.3.1 Increase in outpatient management of anticoagulation therapy 26
3.1.3.2 Development of NOAC reversal agents 27
 
3.2 MARKET DYNAMICS: ANTICOAGULATION CLINICS 28
3.2.1 KEY MARKET DRIVERS 28
3.2.1.1 Increasing prevalence of CVD and blood disorders 28
3.2.1.2 High level of medication adherence 29
3.2.1.3 Growth in the geriatric population 29
3.2.2 MARKET RESTRAINTS 30
3.2.2.1 Rising adoption of NOACs 30
3.2.2.2 Demand for alternative treatments 31
3.2.2.3 Home PT/INR testing 31
3.2.3 MARKET OPPORTUNITIES 32
3.2.3.1 Development of alternative approaches 32
4 MARKET INSIGHTS 33
4.1 INTRODUCTION 33
4.2 NUMBER OF ANTICOAGULATION CLINICS 33
4.3 BUSINESS MODELS OF ANTICOAGULATION CLINICS 34
4.3.1 REVENUE STRUCTURE 34
4.3.2 INFRASTRUCTURE REQUIREMENTS FOR SUSTAINING IN THE MARKET 35
4.3.2.1 Role of teleconsultation and telemonitoring 35
4.3.2.2 Role of electronic health record in anticoagulation clinics 37
4.4 REIMBURSEMENT SCENARIO (CMS & PRIVATE PAYERS) 37
4.4.1 REIMBURSEMENT RATE (2016–2017) 37
4.4.1.1 Reimbursement for PT/INR testing 37
4.4.1.2 Reimbursement for evaluation and management service associated with anticoagulation therapy 45
4.4.2 REIMBURSEMENT TRENDS FOR ANTICOAGULATION THERAPY 46
4.5 IMPACT OF NEW ORAL ANTICOAGULANTS (NOACS) ON ANTICOAGULATION CLINICS 48
5 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET 51
5.1 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR DRUGS 52
5.1.1 INTRODUCTION 52
5.1.2 NOVEL ORAL ANTICOAGULANTS 54
5.1.3 WARFARIN (VITAMIN K ANTAGONIST) 55
5.1.4 OTHER DRUGS 55
5.2 US ANTICOAGULATION THERAPY (PRODUCTS) MARKET FOR PT/INR TESTING DEVICES 56
5.2.1 INTRODUCTION 56
5.2.2 IN-OFFICE TESTING DEVICES 57
5.2.3 HOME TESTING DEVICES 58
 
6 US ANTICOAGULATION THERAPY MARKET FOR CLINICS 59
6.1 INTRODUCTION 60
6.2 US ANTICOAGULATION THERAPY MARKET FOR CLINICS, BY TYPE OF SERVICE 60
6.2.1 INTRODUCTION 60
6.2.2 TESTING SERVICES 62
6.2.3 CONSULTING SERVICES 62
6.3 US ANTICOAGULANT THERAPY MARKET FOR CLINICS, BY TYPE OF CLINIC 63
6.3.1 INTRODUCTION 63
6.3.2 HOSPITAL ASSOCIATED CLINICS 65
6.3.3 INDEPENDENT CLINICS 66
6.3.4 PHARMACY-BASED CLINICS 66
7 COMPANY PROFILES 67
(BUSINESS OVERVIEW, PRODUCTS OFFERED, STRENGTH OF PRODUCT PORTFOLIO, BUSINESS STRATEGY EXCELLENCE, RECENT DEVELOPMENTS.)*
7.1 INTRODUCTION 67
7.2 HOME TESTING DEVICES MANUFACTURERS 67
7.2.2 ABBOTT LABORATORIES 69
7.2.3 SIEMENS AG 71
7.2.4 COAGUSENSE, INC. 73
7.2.5 ALERE INC. 74
7.3 DRUG MANUFACTURERS 76
7.3.1 C. H. BOEHRINGER SOHN AG & CO. KG 76
7.3.2 BRISTOL-MYERS SQUIBB COMPANY 78
7.3.3 JOHNSON & JOHNSON 80
7.3.4 PFIZER, INC. 82
7.3.5 DAIICHI SANKYO COMPANY, LIMITED 84
7.3.6 PORTOLA PHARMACEUTICALS, INC. 86